澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

INVION LTD

0.081

0.000

成交量：264.00

成交額：21.00

市值：693.74萬

市盈率：-0.66

高：0.081

開：0.081

低：0.081

收：0.081

52周最高：0.200

52周最低：0.075

股本：8,564.73萬

流通股本：5,674.14萬

量比：0.01

換手率：0.00%

股息：- -

股息率：- -

每股收益(TTM):-0.122

每股收益(LYR):-0.122

淨資產收益率：-77.64%

總資產收益率：-44.16%

市淨率：0.84

市盈率(LYR):-0.66

資料載入中...

總覽公司新聞資訊公告

INVION LTD - 從Hanlim藥業和韓國政府研究基金獲得的非稀釋性資金用於食道癌臨床前項目

BUZZ-新月生物製藥公司在合作開發抗癌藥物後業績大增

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/IVX.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IVX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IVX.AU\",,,,,undefined,":{"symbol":"IVX.AU","market":"AU","secType":"STK","nameCN":"INVION LTD","latestPrice":0.081,"timestamp":1771978919798,"preClose":0.081,"halted":0,"volume":264,"delay":0,"changeRate":0,"nameEN":"INVION LTD","floatShares":56741426,"shares":85647255,"eps":-0.122249,"marketStatus":"交易中","change":0,"latestTime":"02-25 13:44:20 AEDT","open":0.081,"high":0.081,"low":0.081,"amount":21,"amplitude":0,"askPrice":0.084,"askSize":81035,"bidPrice":0.081,"bidSize":133729,"shortable":3,"etf":0,"ttmEps":-0.122249,"tradingStatus":2,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1771995600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.081,"openAndCloseTimeList":[[1771974000000,1771995600000]],"volumeRatio":0.008634,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IVX.AU\",,,,,undefined,":{"symbol":"IVX.AU","floatShares":56741426,"roa":"-44.16%","roe":"-77.64%","lyrEps":-0.122249,"volumeRatio":0.008634,"shares":85647255,"dividePrice":0,"high":0.081,"amplitude":0,"preClose":0.081,"low":0.081,"week52Low":0.075,"pbRate":"0.84","psRate":"2300.97","week52High":0.2,"institutionHeld":0,"latestPrice":0.081,"committee":0.245358,"eps":-0.122249,"divideRate":0,"volume":264,"delay":0,"ttmEps":-0.122249,"open":0.081,"prevYearClose":0.093,"prevWeekClose":0.082,"prevMonthClose":0.092,"prevQuarterClose":0.093,"fiveDayClose":0.085,"twentyDayClose":0.092,"sixtyDayClose":0.08},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IVX.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-11-20","symbol":"IVX.AU","defaultRemindTime":1732057200000,"type":"split","dateTimestamp":1732021200000,"forFactor":100,"toFactor":1,"ratio":100}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IVX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IVX.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1186267120","title":"INVION LTD - 從Hanlim藥業和韓國政府研究基金獲得的非稀釋性資金用於食道癌臨床前項目","url":"https://stock-news.laohu8.com/highlight/detail?id=1186267120","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186267120?lang=zh_tw&edition=fundamental","pubTime":"2025-12-23 06:39","pubTimestamp":1766443149,"startTime":"0","endTime":"0","summary":"INVION LTD - 从Hanlim药业和韩国政府研究基金获得的非稀释性资金用于食道癌临床前项目","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7509","IVX.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2588813678","title":"BUZZ-新月生物製藥公司在合作開發抗癌藥物後業績大增","url":"https://stock-news.laohu8.com/highlight/detail?id=2588813678","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588813678?lang=zh_tw&edition=fundamental","pubTime":"2025-12-04 20:24","pubTimestamp":1764851059,"startTime":"0","endTime":"0","summary":"BUZZ-新月生物制药公司在合作开发抗癌药物后业绩大增12月4日 - ** 新月生物制药CBIO.O股价盘前上涨36.5%至18.30美元 ** 公司称已与中国科伦生物技术公司建立独家合作伙伴关系，共同开发和销售新型癌症治疗药物** 公司还将向投资者募集 1.85 亿美元，用于资助临床试验 - CBIO** 凯伦生物技术公司获得了该公司实验药物CR-001在大中华区的销售权。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nL4T3XA0VZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1979443071.USD","BK7508","LU0196878994.USD","LU1064131003.USD","BK7509","LU1064130708.USD","BK0060","06990","BK1161","BK7096","BK4139","LU1934453819.USD","LU2148510915.USD","IVX.AU","002422","BK0239","CBIO"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}]}}